Adalta Share Price and Company Fundamentals
Last traded: Yesterday at 11:34 PM
AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. It has discovered WD-34 for the multiple malaria species, Babesia, and Toxoplasma in collaboration with La Trobe University. The company was incorporated in 2006 and is based in Camberwell, Australia.
Key Metrics
PE ratio
-
PB ratio
-
Dividend yield
-
Beta
0.14
Market cap
$10.33M
Enterprise value
$1.02M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Full time employees | 1 |
| Website | https://www.adalta.com.au |
| Mailing address | 697 Burke Road Suite 201 Camberwell VIC 3124 Australia |
| Phone / Fax | 61 3 9479 5159 / 61 2 8583 3040 |
Dividends
More: Adalta Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Adalta paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.1AD dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Adalta.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Timothy Charles Oldham B.Sc., BSc(Hons), L.L.B., LLB(Hons), Ph.D. | CEO, MD & Director | ||
| Mr. Angus Tester Ph.D. | Senior Director of Operations | ||
| Prof. Michael Foley Ph.D. | Founding Chief Scientist | ||
| Dr. Andrew Peter O'Brien MBA., Ph.D. | Head of Corporate Development | 56 | |
| Ms. Janette Dixon | Head of Business Development | ||
| Dr. Kevin Patrick Lynch FFPM, M.D., MBBS | Consultant Chief Medical Officer of Oncology | 60 | |
| Mr. Cameron Peter Jones C.A. | Company Secretary |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-636.83%
Return on assets
-72.30%
Return on equity
-628.72%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Adalta is 10.33M and its enterprise value is 1.02M. The enterprise value to revenue ratio of 1AD is 1.50. The enterprise value to EBITDA ratio of 1AD is -0.23.
The 1AD's stocks Beta value is 0.14 making it 86% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Adalta (1AD)
Adalta (ASX:1AD) Frequently Asked Questions
1. What is Adalta's Stock Symbol?
Adalta trades on ASX under the ticker symbol "1AD".
2. What is Adalta's stock price today?
One share of 1AD stock can currently be purchased for approximately $0.0045.
3. How can I contact Adalta?
Adalta's mailing address is 697 Burke Road Suite 201 Camberwell VIC 3124 Australia. The company can be reached via phone at 61 3 9479 5159.
4. What is Adalta's official website?
The official website of Adalta is https://www.adalta.com.au.